US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

1.73

-0.0900-4.95%

Post-market: 1.780.0500+2.89%17:51 EDT

Volume:491.16K

Turnover:849.14K

Market Cap:199.41M

PE:-2.51

High:1.84

Open:1.81

Low:1.71

Close:1.82

52wk High:6.79

52wk Low:1.46

Shares:115.27M

Float Shares:64.56M

Volume Ratio:1.82

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6900

EPS(LYR):-0.9225

ROE:-59.10%

ROA:-34.98%

PB:0.99

PE(LYR):-1.88

Loading ...

Overview Company News Filings

NovaBridge Biosciences CMO Dennis Phillip Andrew disposes of ordinary shares worth $5,606.04

NovaBridge Biosciences replaces PwC with Deloitte as auditor

NovaBridge Biosciences Gains US FDA Fast Track Status for Gastroesophageal Cancer Therapy

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye

NovaBridge wins FDA fast track for givastomig combo in first-line HER2-negative metastatic gastric cancer

Novabridge Biosciences - Registrational Phase 3 Trial for Givastomig Expected to Begin as Early as Q4 2026

THOMSON REUTERS

Novabridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer

THOMSON REUTERS

Novabridge Biosciences - Detailed Phase 1B Data for Givastomig Expected in H2 2026

THOMSON REUTERS

NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36

Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list

Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth

Simply Wall St.

H.C. Wainwright Sticks to Its Buy Rating for NovaBridge Biosciences (NBP)

NovaBridge management to join H.C. Wainwright BioConnect Investor Conference fireside chat

Insider’s Bold Move Signals Rising Confidence in NovaBridge Biosciences

NovaBridge President, CCO Hagler acquires $577,300 common shares

Extended ceasefire only prolongs market uncertainty, gold’s medium-term prospects strengthen while silver demand slides – Heraeus

NovaBridge Biosciences’ Hagler named president, chief commercial officer, files Form 3 ownership statement

NovaBridge names Mark Hagler president and chief commercial officer

Press Release: NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/NBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":1.73,"timestamp":1788292800000,"preClose":1.82,"halted":0,"volume":491160,"hourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.73,"latestTime":"17:51 EDT","volume":754,"amount":1328.3062676,"timestamp":1788299463202,"change":0.05,"changeRate":0.028902,"amplitude":0.028902},"delay":0,"changeRate":-0.04945054945054949,"floatShares":64563600,"shares":115266053,"eps":-0.69,"marketStatus":"Post-Mkt","change":-0.09,"latestTime":"09-01 18:24:39 EDT","open":1.81,"high":1.835,"low":1.705,"amount":849141.47484,"amplitude":0.071429,"askPrice":1.85,"askSize":5,"bidPrice":1.7,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-0.69,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.82,"preHourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.82,"latestTime":"09:29 EDT","volume":631,"amount":1140.1852607,"timestamp":1788269399912,"change":-0.01,"changeRate":-0.005495,"amplitude":0.020934},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.73,"latestTime":"17:51 EDT","volume":754,"amount":1328.3062676,"timestamp":1788299463202,"change":0.05,"changeRate":0.028902,"amplitude":0.028902},"volumeRatio":1.824909,"impliedVol":1.8929,"impliedVolPercentile":0.7714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64563600,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":1.824909,"shares":115266053,"dividePrice":0,"high":1.835,"amplitude":0.071429,"preClose":1.82,"low":1.705,"week52Low":1.46,"pbRate":"0.99","week52High":6.79,"institutionHeld":0,"latestPrice":1.73,"committee":0.666667,"eps":-0.69,"divideRate":0,"volume":491160,"delay":0,"ttmEps":-0.69,"open":1.81,"prevYearClose":3.98,"prevWeekClose":1.84,"prevMonthClose":1.82,"prevQuarterClose":1.95,"fiveDayClose":1.93,"twentyDayClose":1.65,"sixtyDayClose":1.645},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"Pre-MKt","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-08-31","current":-2.507246,"percent":1,"low":-20.276437,"twenty":-14.530716,"median":-10.641845,"eighty":-2.330251,"high":-1.815664,"avg":-8.487928,"sd":6.074301,"marketCap":213438557},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642},{"date":"2026-08-28","current":-1.865003,"twenty":-14.539475,"median":-10.707535,"eighty":-2.330251,"marketCap":219238518},{"date":"2026-08-31","current":-1.815664,"twenty":-14.530716,"median":-10.641845,"eighty":-2.330251,"marketCap":213438557}],"updateTime":1788301479107},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645900894","title":"NovaBridge Biosciences CMO Dennis Phillip Andrew disposes of ordinary shares worth $5,606.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2645900894","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645900894?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:24","pubTimestamp":1782163461,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew sold 8,494 ordinary shares on June 18 at USD 0.66.Holdings fell to 157,941 ordinary shares following the sale.Andrew also acquired 23,695 ordinary shares on June 17 via an equity award transaction.He reported 82,422 restricted share units after the June 17 vesting-related transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbMrgn7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NovaBridge Biosciences CMO Dennis Phillip Andrew disposes of ordinary shares worth $5,606.04","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760741","title":"NovaBridge Biosciences replaces PwC with Deloitte as auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760741","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760741?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:40","pubTimestamp":1781642455,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences replaced PwC as independent auditor with Deloitte, effective June 16, 2026, for the fiscal year ending Dec. 31, 2026.PwC audit opinions for fiscal 2025 and 2024 were clean, with no adverse opinion, disclaimer, or scope or accounting qualifications.No reported auditor disagreements; the only cited reportable issue was material weaknesses in IT general controls at Dec. 31, 2025 and 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL4jzk5k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575487","title":"NovaBridge Biosciences Gains US FDA Fast Track Status for Gastroesophageal Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575487","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575487?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:41","pubTimestamp":1781610076,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences  said Tuesday the US Food and Drug Administration granted fast track designation to its experimental therapy, givastomig, in combination with nivolumab and chemotherapy, for certain previously untreated patients with HER2-negative advanced or metastatic gastroesophageal adenocarcinoma.The company said the fast track designation is intended to accelerate the development and regulatory review of therapies that address serious conditions and unmet medical needs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4585","BK4139","NBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751790","title":"BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643751790?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609654,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL6N42O0S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOX","HOOD","LU0868494617.USD","BK4588","BK4554","BK4141","BK4196","LU0868494708.USD","QCML","BK4539","QCMD","BK4157","BK4573","SG9999015978.USD","BK4124","HOOW","LU1861559042.SGD","LU1069344957.HKD","LU2023250504.SGD","LU2065171402.SGD","HIMY","LU1066051498.USD","BK4098","HMYY","IE00BVYPNQ40.USD","BK4127","HOYY","LU1823568750.SGD","LU2247934214.USD","NBP","BK4231","LU2065169927.USD","LU2106854487.HKD","LU1084165304.USD","LU1066053197.SGD","HOOG","SG9999002224.SGD","LU0079474960.USD","LU2065171311.SGD","HUN","BK4515","BK4605","SG9999015986.USD","QCOM","BK4080","MBLY","SG9999015952.SGD","LU1035775433.USD","BK4585","BK4575","QCMU","BK4612","HOOY","LU1861558580.USD","BK4561","BK4604","IE00BGHQDM52.EUR","SG9999002232.USD","BK4581","MAC","HIMZ","HOOI","LU2065170008.USD","HOOZ","LU1119994496.HKD","BK4534","ALVO","LU1244550577.SGD","LU1046421795.USD","BK4532","BK4547","HODU","IE00BVYPNP33.GBP","HIMS","ROBN","LU0061475181.USD","BK4527","LU1244550221.USD","IE00BSNM7G36.USD","BK4579","LU0081259029.USD","SG9999015945.SGD","LU0942090050.USD","SG9999001424.SGD","LU1261432733.SGD","LU1917777945.USD","LU1066051811.HKD","BK4551","GB00BDT5M118.USD","LU0054578231.USD","HIYY","LU1066051225.USD","BK4598","LU1496350502.SGD","HOII","LU1244550494.USD","BK4139","LU1974910355.USD","BK4512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759457","title":"NovaBridge wins FDA fast track for givastomig combo in first-line HER2-negative metastatic gastric cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759457","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759457?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:01","pubTimestamp":1781607680,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences received FDA Fast Track designation for givastomig with nivolumab and chemotherapy in first-line HER2-negative metastatic GEA.Early-stage findings showed strong anti-tumor activity with manageable tolerability, supporting further development in a biomarker-selected population.A registrational Phase 3 trial is expected to start as early as Q4 2026, setting up the next major value inflection point.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL65dnHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759675","title":"Novabridge Biosciences - Registrational Phase 3 Trial for Givastomig Expected to Begin as Early as Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759675?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575962","title":"Novabridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575962?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275918","title":"Novabridge Biosciences - Detailed Phase 1B Data for Givastomig Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275918?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640853921","title":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2640853921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640853921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:47","pubTimestamp":1780440460,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported an RSU vesting into 9,382 ordinary shares on May 30, 2026.Xu sold 3,494 ordinary shares on June 1, 2026 at USD 3.94 per share.Directly owned ordinary shares stood at 290,154 following the sale.Directly held restricted share units totaled 32,637 after the vesting transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7FngBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640393487","title":"Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list","url":"https://stock-news.laohu8.com/highlight/detail?id=2640393487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640393487?lang=en_us&edition=fundamental","pubTime":"2026-06-01 16:09","pubTimestamp":1780301388,"startTime":"0","endTime":"0","summary":"Hangzhou State Capital Investment and Operations reported multiple direct-investment portfolio companies ranked in the “2026 Future Healthcare 100” lists.Innovation devices, intelligent manufacturing Top 100: BrainCo; ChengTian Technology.Innovative drugs, biologics Top 100: Qihan Bio; Linke Pharma; Haichang Bio; Triastek; Kejun Pharma; Lingyi Bio.Health services, industry-chain services Top 100: Ailios; Heiyu Science.Other invested companies cited in the sector: Deepwise AI Lab; Yangli Pharma; Nurotron; I-Mab; Yuyan Pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou State Capital Investment and Operations Co Ltd published the original content used to generate this news brief on June 01, 2026, and is solely responsible for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5rn0qQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688769","title":"Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688769?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:17","pubTimestamp":1779880679,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbp/novabridge-biosciences/news/companies-like-novabridge-biosciences-nasdaqnbp-can-afford-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbp/novabridge-biosciences/news/companies-like-novabridge-biosciences-nasdaqnbp-can-afford-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JEPQ","PSQ","GPIQ","IYW","QQQY","QQQJ","QQQE","QQQA","BK4139","ONEQ","FTEC","QDTE","NDX","TQQQ","MNQmain","SQQQ","NVIW.SI","NQmain","TQQY",".IXIC","QLD","TECS","QID","QYLG","QQQM","QQQ","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638544518","title":"H.C. Wainwright Sticks to Its Buy Rating for NovaBridge Biosciences (NBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638544518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638544518?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:45","pubTimestamp":1779817523,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on NovaBridge Biosciences, with a price target of $9.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-novabridge-biosciences-nbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-novabridge-biosciences-nbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634187522","title":"NovaBridge management to join H.C. Wainwright BioConnect Investor Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2634187522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634187522?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:04","pubTimestamp":1778583868,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences management to join H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbdTtvS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","LU2210149790.SGD","NDAQ","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4585","BK4112","IE00BKPKM429.USD","NBP","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551385","title":"Insider’s Bold Move Signals Rising Confidence in NovaBridge Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631551385?lang=en_us&edition=fundamental","pubTime":"2026-04-29 10:03","pubTimestamp":1777428208,"startTime":"0","endTime":"0","summary":"New insider activity at NovaBridge Biosciences ( ($NBP) ) has taken place on April 28, 2026. Mark Arnold Hagler has significantly increased his sta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-bold-move-signals-rising-confidence-in-novabridge-biosciences-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-bold-move-signals-rising-confidence-in-novabridge-biosciences-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631533182","title":"NovaBridge President, CCO Hagler acquires $577,300 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2631533182","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631533182?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:08","pubTimestamp":1777406903,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences President, Chief Commercial Officer Mark Arnold Hagler reported a purchase of 230,000 ordinary shares at USD 2.51 per share.Beneficial ownership stood at 230,000 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLcgH4fC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NovaBridge President, CCO Hagler acquires $577,300 common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031303","title":"Extended ceasefire only prolongs market uncertainty, gold’s medium-term prospects strengthen while silver demand slides – Heraeus","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031303","media":"Kitco","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630031303?lang=en_us&edition=fundamental","pubTime":"2026-04-27 14:49","pubTimestamp":1777272540,"startTime":"0","endTime":"0","summary":"(Kitco News) – The ceasefire between the U.S. and Israel and Iran is beginning to turn the conflict into a prolonged one, which markets don’t seem to fully grasp, and while the bull market for gold sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"kitco_highlight","url":"https://www.kitco.com/news/article/2026-04-27/extended-ceasefire-only-prolongs-market-uncertainty-golds-medium-term","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.kitco.com/news/article/2026-04-27/extended-ceasefire-only-prolongs-market-uncertainty-golds-medium-term","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"kitco_highlight","symbols":["BK4588","1OZmain","SILJ","ZSL","GDXY","DGP","BK4547","AAAU","GBUG","GLL","BK4504","PHYS","SLVP","FGDL","GDXD","OUNZ","SIVR","BTGD","IAUM","IAUI","SIL","BEGS","GDXJ","DUST","GLTR","GDX","DULL","GOLY","SLVR","KSLV","DZZ","BK4207","RING","SGOL","SLV","XME","AGQ","CEF","IAU","JDST","GLDM","UGL","PSLV","GDXU","USG","BAR","DBC","NBP","PICK","JNUG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629802034","title":"NovaBridge Biosciences’ Hagler named president, chief commercial officer, files Form 3 ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629802034","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629802034?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:09","pubTimestamp":1776888599,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences filed an initial Form 3 for Mark Arnold Hagler, president and chief commercial officer, dated April 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL62M1ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629704864","title":"NovaBridge names Mark Hagler president and chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629704864","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629704864?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:08","pubTimestamp":1776856090,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences appointed Mark Hagler as president and chief commercial officer.Hagler previously built commercial strategy for Abraxane in new indications.He also led global launch of a core Afinitor indication.Role adds commercial leadership as NovaBridge advances givastomig toward registrational pivotal studies in first-line gastric cancer.Appointment also supports pre-commercial readiness for VIS-101, a dual VEGF-A x ANG-2 inhibitor program in wet AMD.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL7bgG9l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4112","NBP","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629104060","title":"Press Release: NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2629104060","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629104060?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"-- Seasoned Biopharma leader bringing deep commercial experience to shape. and inform corporate strategy, clinical trial design and business. givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific. potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD. \"Welcoming Mark adds meaningful commercial and operational leadership experience to NovaBridge. This year, NovaBridge has demonstrated strong momentum, with compelling clinical data from our two mid-stage, potential best-in-class/first-in-class programs, givastomig and VIS-101. As we progress towards pivotal studies, Mark's perspective will be instrumental in defining our path forward to maximize the value of our pipeline for shareholders and patients,\" said Fu Wei, Executive Chairman of the Board of NovaBridge.\"Joining NovaBridge at this pivotal time is incredibly exciting. I look forward to partnering with my colleagues as we advance givastomig and VIS-101 to pivotal studies. The pipeline is supported by co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BK4022","NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494826","title":"NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494826?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:56","pubTimestamp":1775645760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 06:56 ET (10:56 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":71,"code":"91000000","status":"200"}]}}